BioNTech SE (BNTX) AI Stock Analysis

• Market Cap: $22.03B
• Dividend Yield: N/A
• Average Volume (3M): 1.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 7.04%
• EPS Growth: -25.24%
• Country: US
• Employees: 6,772
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 240,455,440
• 10 Day Avg. Volume: 1,211,698
• 30 Day Avg. Volume: 1,210,078
• PEG Ratio: 0.23
• Price to Book (P/B): 1.36
• Price to Sales (P/S): 9.62
• P/FCF Ratio: -108.15
• Enterprise Value/Market Cap: 0.32
• Enterprise Value/Revenue: 2.25
• Enterprise Value/Gross Profit: 2.73
• Enterprise Value/Ebitda: -68.81
• 1Y Price Target: $141.93
• Price Target Upside: 55.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $105.00 ▲(14.80% Upside)

BioNTech's overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.

Positive Factors

Oncology Pipeline Progress

Advancements in the oncology pipeline, particularly with Pumitamig, position BioNTech for potential product launches, enhancing long-term growth prospects.

Strategic Partnerships

The partnership with Bristol-Myers Squibb strengthens BioNTech's oncology market position and provides significant financial benefits, supporting sustainable growth.

Strong Financial Position

A robust financial position with substantial cash reserves ensures BioNTech can fund its oncology transition and invest in long-term growth initiatives.

Negative Factors

Net Loss and Profitability Challenges

Ongoing net losses highlight profitability challenges, which could strain financial resources and impact long-term sustainability if not addressed.

Cash Flow Issues

Declining cash flow growth indicates potential liquidity constraints, which could limit BioNTech's ability to invest in R&D and operational expansion.

Regulatory Delays

Regulatory delays in product submissions can hinder BioNTech's ability to bring new treatments to market, affecting revenue and competitive positioning.

BioNTech SE Business Overview & Revenue Model

Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

How the Company Makes Money

BioNTech generates revenue primarily through the sale of its COVID-19 vaccine, Comirnaty, in collaboration with Pfizer, which has significantly contributed to its earnings since its launch. The revenue model includes direct sales to governments and healthcare providers, as well as potential royalties from future sales. In addition to vaccine sales, BioNTech's revenue streams are diversified through partnerships with pharmaceutical companies, research collaborations, and grants for developing other mRNA-based therapies. The company also engages in clinical trials and advancements in its pipeline of cancer therapies, which may lead to future monetization through licensing agreements or product sales upon successful commercialization. Strategic collaborations with entities like Pfizer and other biotech firms further bolster its financial performance and market reach.

BioNTech SE Financial Statement Overview

Summary

BioNTech SE faces challenges with recent financial losses impacting profitability metrics. Despite strong historical growth, the company is dealing with operational and cash flow issues. However, the balance sheet remains robust with low leverage, providing a cushion to address these issues.

Income Statement

BioNTech SE has experienced significant volatility in its income statement metrics. The company showed strong revenue growth in the past but has faced a decline in recent years. The TTM data indicates a slight revenue growth of 9.52%, but the company is currently operating at a net loss with a negative net profit margin of -12.07%. The gross profit margin remains strong at 79.76%, indicating efficient production, but negative EBIT and EBITDA margins suggest operational challenges.

Balance Sheet

The balance sheet of BioNTech SE is relatively strong, with a low debt-to-equity ratio of 0.0146, indicating minimal leverage and financial risk. However, the return on equity is negative at -1.83%, reflecting recent profitability challenges. The equity ratio is healthy, suggesting a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

BioNTech SE's cash flow statement reveals challenges, with a significant decline in free cash flow growth at -57.32% TTM. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to earnings. However, the free cash flow to net income ratio is positive at 1.48, suggesting some ability to generate cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.15B	2.75B	3.82B	17.31B	18.98B	482.30M
Gross Profit	2.60B	2.21B	3.22B	14.32B	16.07B	423.00M
EBITDA	-103.30M	-367.10M	1.38B	13.10B	15.00B	-105.10M
Net Income	-571.60M	-665.30M	930.30M	9.43B	10.29B	15.20M
Balance Sheet
Total Assets	21.34B	22.53B	23.01B	23.28B	15.83B	2.32B
Cash, Cash Equivalents and Short-Term Investments	14.53B	16.78B	16.55B	14.06B	2.07B	1.35B
Total Debt	245.40M	254.20M	219.10M	212.20M	301.50M	240.10M
Total Liabilities	2.86B	3.12B	2.76B	3.22B	3.94B	946.80M
Stockholders Equity	18.48B	19.41B	20.25B	20.06B	11.89B	1.37B
Cash Flow
Free Cash Flow	-562.71M	-244.60M	4.67B	13.21B	735.70M	-98.90M
Operating Cash Flow	-336.14M	207.70M	5.37B	13.58B	889.70M	-13.50M
Investing Cash Flow	938.93M	-2.08B	-6.95B	-35.30M	-566.10M	-144.80M
Financing Cash Flow	-51.58M	-45.90M	-778.60M	-1.42B	94.20M	894.70M

BioNTech SE Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 91.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Negative. The current price of 91.46 is below the 20-day moving average (MA) of 96.07, below the 50-day MA of 101.04, and below the 200-day MA of 102.83, indicating a bearish trend. The MACD of -2.60 indicates Positive momentum. The RSI at 35.97 is Neutral, neither overbought nor oversold. The STOCH value of 9.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTX.

BioNTech SE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INCY	81 Outperform	$19.17B	16.32	30.39%	―	18.09%	3563.21%
UTHR	79 Outperform	$22.00B	19.22	20.04%	―	13.50%	17.16%
GMAB	76 Outperform	$19.52B	13.27	28.20%	―	24.98%	127.06%
ROIV	58 Neutral	$15.79B	-39.43	-14.73%	―	-83.82%	-109.22%
MRNA	58 Neutral	$11.92B	-3.84	-29.32%	―	-56.00%	-38.95%
BNTX	53 Neutral	$22.03B	-34.76	-2.94%	―	7.04%	-25.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

BioNTech SE Corporate Events

BioNTech and OncoC4 Report Positive Phase 3 Trial Results for Gotistobart in Lung Cancer

On December 6, 2025, BioNTech SE and OncoC4, Inc. presented promising data from the non-pivotal dose-confirmation stage of their global Phase 3 trial, PRESERVE-003, for gotistobart, a tumor microenvironment-selective regulatory T cell depletion candidate. The trial demonstrated that gotistobart significantly reduced the risk of death by more than half compared to standard chemotherapy in patients with metastatic squamous non-small cell lung cancer (sqNSCLC), showing a clinically meaningful overall survival benefit and a manageable safety profile. The median overall survival for patients treated with gotistobart had not been reached at nearly 15 months of follow-up, compared to 10 months for those on chemotherapy. This development positions gotistobart as a potential chemotherapy-free alternative for sqNSCLC patients with high unmet medical needs, enhancing BioNTech’s standing in the oncology field.

BioNTech Satisfies Minimum Condition in CureVac Exchange Offer

On December 3, 2025, BioNTech SE announced that it has satisfied the minimum condition of its exchange offer for CureVac N.V., with 81.74% of CureVac’s shares tendered. The subsequent offering period has commenced, allowing remaining CureVac shareholders to tender their shares until December 18, 2025. The completion of this exchange offer will lead to a post-offer reorganization, impacting the tradability of CureVac shares and subjecting non-tendering shareholders to a Dutch dividend withholding tax. This strategic move strengthens BioNTech’s position in the biopharmaceutical industry by expanding its portfolio and market reach.

BioNTech Advances with CureVac Exchange Offer Approval

On November 26, 2025, BioNTech SE announced the approval of its exchange offer for all outstanding shares of CureVac N.V., following an extraordinary general meeting held by CureVac on November 25, 2025. The offer, which expires on December 3, 2025, involves an exchange ratio of 0.05363 BioNTech ADS per CureVac share. The transaction aims to strengthen BioNTech’s market position by acquiring at least 80% of CureVac’s shares, with a potential reduction to 75% if conditions are met. This strategic move is expected to enhance BioNTech’s capabilities in the biopharmaceutical industry, benefiting stakeholders by expanding its portfolio and market reach.

BioNTech Unveils Strategic Advances at R&D Day 2025

On November 11, 2025, BioNTech SE hosted its Innovation Series R&D Day, where it outlined its strategic direction and clinical advancements across its pipeline. The event highlighted BioNTech’s unique approach to innovation and its differentiated clinical strategy in oncology, including the development of mRNA cancer immunotherapies. The presentation emphasized the company’s ongoing efforts to establish Pumitamig1 in foundational tumor types and its partnership with Bristol Myers Squibb. This event reflects BioNTech’s commitment to advancing cancer treatment and its continued impact on the biotechnology industry.

BioNTech Reports Q3 2025 Financials and Raises Revenue Guidance

On November 3, 2025, BioNTech SE announced its third-quarter financial results, highlighting a revenue increase to €1.5 billion, despite a net loss of €28.7 million. The company reported progress in its oncology strategy, particularly with the bispecific antibody candidate pumitamig, and launched a variant-adapted COVID-19 vaccine for the 2025/2026 season. BioNTech also raised its full-year revenue guidance to €2.6-2.8 billion, supported by a $1.5 billion payment from its partnership with Bristol Myers Squibb.

BioNTech Reports Q3 2025 Financial Results with Revenue Growth Amid Operating Loss

On November 3, 2025, BioNTech SE announced its financial results for the three and nine months ending September 30, 2025. The company reported revenues of €1,518.9 million for the third quarter, reflecting a significant increase from the previous year. However, despite the revenue growth, BioNTech experienced an operating loss of €46.9 million for the quarter, attributed to increased research and development expenses and other operating costs. This financial update highlights the company’s ongoing investment in its pipeline and the challenges of balancing revenue growth with operational costs.

BioNTech Launches Exchange Offer for CureVac Shares to Boost Oncology Strategy

On October 22, 2025, BioNTech SE announced the commencement of a public exchange offer for all outstanding shares of CureVac N.V., as part of a strategic acquisition to enhance its capabilities in mRNA-based cancer immunotherapy. This acquisition is expected to strengthen BioNTech’s research, development, manufacturing, and commercialization efforts, marking a significant milestone in its oncology strategy. The transaction, valued at approximately $1.25 billion, aims to create long-term value for shareholders and advance the development of innovative cancer treatments.

BioNTech Hosts Second AI Day to Showcase AI Integration

On October 1, 2025, BioNTech SE, in collaboration with InstaDeep Ltd., hosted its second AI Day as part of its Innovation Series. The event highlighted BioNTech’s AI strategy and its application in the company’s pipeline and internal processes. This initiative underscores BioNTech’s commitment to leveraging AI to advance its position in the biotechnology industry, potentially impacting its operational efficiency and stakeholder engagement.

BioNTech and BMS Reveal Promising Phase 2 Results for Lung Cancer Treatment

On September 8, 2025, BioNTech SE and Bristol Myers Squibb presented interim data from a Phase 2 trial evaluating pumitamig, a bispecific antibody, in patients with extensive-stage small cell lung cancer. The data showed promising antitumor activity, with a 76.3% confirmed objective response rate and a 100% disease control rate, suggesting potential for pumitamig to become a new standard of care in this aggressive cancer type. The trial’s results are being used to inform a global Phase 3 trial, and pumitamig has received Orphan Drug designation from the FDA.

BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy

On June 2, 2025, BioNTech SE entered into a Global Co-Development and Co-Commercialization Agreement with Bristol-Myers Squibb Company to develop, manufacture, and commercialize the bispecific antibody BNT327 for various solid tumor types. The agreement, which was amended on August 15, 2025, includes a $1.5 billion upfront payment to BioNTech and up to $7.6 billion in additional milestone payments. The collaboration will see both companies sharing profits and losses equally, with a focus on maximizing the success and efficiency of BNT327’s development and commercialization. This strategic partnership is expected to enhance BioNTech’s position in the oncology market and provide significant financial benefits.